ALL

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Prudential Securities Litigation

Retrieved on: 
Monday, April 8, 2024
Class Action Lawsuit, Professional Services, Legal, COMMON, Class Action, Failure, Prejudice, Notice, Prudential, District court, Telephone, ALL, Class, Episcopal conference, THIS, Judgement, Lawsuit, Court, Hearing, INC

The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Prudential Securities Litigation:

Key Points: 
  • The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Prudential Securities Litigation:
    TO: ALL PERSONS AND ENTITIES WHO PURCHASED THE COMMON STOCK OF PRUDENTIAL FINANCIAL, INC.
  • BETWEEN JUNE 5, 2019 AND AUGUST 2, 2019, INCLUSIVE (“CLASS” OR “CLASS MEMBERS”)
    THIS NOTICE WAS AUTHORIZED BY THE COURT.
  • Also, if the Court requires or allows Class Members to participate in the Settlement Hearing by telephone or videoconference, the access information will be posted to the Settlement website, www.PrudentialSecuritiesSettlement.com .
  • IF YOU PURCHASED PRUDENTIAL COMMON STOCK BETWEEN JUNE 5, 2019 AND AUGUST 2, 2019, INCLUSIVE, YOUR RIGHTS ARE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION.

Allterum Therapeutics receives $12 million product development grant from CPRIT to advance anti-CD127 therapeutic antibody into clinic

Retrieved on: 
Monday, April 8, 2024
NCI, Acute lymphoblastic leukemia, CLL, Immunotherapy, AML, TTC, Lung, Patient, ALL, NeXT, National Cancer Institute, Breast, Cancer, Pediatrics, Doctor of Philosophy, IND, GMP, Clinical trial, Investigational New Drug, Therapy, Immune system, Prognosis, Research institute, Cancer prevention, FDA, Lymphoma, CD127, Pharmaceutical industry

HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which will support the clinical evaluation of Allterum's lead candidate, 4A10, a monoclonal antibody targeting CD127. CD127 is a receptor that is expressed in major subsets of multiple cancers including hematological cancers (ALL, AML, CLL, and lymphoma) and solid tumors (lung, breast, colorectal, H&N, esophageal cancers).

Key Points: 
  • Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which will support the clinical evaluation of Allterum's lead candidate, 4A10, a monoclonal antibody targeting CD127.
  • An addition to the $12M Product Development Award, Allterum received a $2.9M CPRIT seed award in 2020, which supported early-stage development work for the 4A10 antibody and laid the foundation for the current grant.
  • "We are pleased to provide Allterum with this TTC product development award to advance their promising anti-cancer drug into clinic," said Dr. Kenneth Smith, CPRIT's Chief Product Development Officer.

Notice of Pendency of Class Action Involving All Persons and Entities who Held Shares of Alta Mesa Silver Run II Common Stock and Purchased or Otherwise Acquired Securities of Alta Mesa / Silver Run II

Retrieved on: 
Monday, April 8, 2024
COMMON, Class Action, PART, Documentation, Action, Alta Mesa AVA, Riverstone Holdings, Notice, Business, Silver, District court, Defendant, ALL, CUSIP, Class, AMH, ARM, Business analyst, Motion, Judgement, CLASS, AMR, HPS, Lis pendens, Court, Docket (court), Person

IN RE ALTA MESA RESOURCES, INC.

Key Points: 
  • IN RE ALTA MESA RESOURCES, INC.
    TO: (1) ALL PERSONS AND ENTITIES WHO HELD SHARES OF ALTA MESA (SILVER RUN II) COMMON STOCK AND/OR SILVER RUN II UNITS ON JANUARY 22, 2018; AND (2) ALL PERSONS AND ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SECURITIES OF ALTA MESA / SILVER RUN II FROM AUGUST 16, 2017 THROUGH MAY 17, 2019, INCLUSIVE (THE "CLASS PERIOD").
  • THIS NOTICE IS NOT A SETTLEMENT NOTICE AND YOU ARE NOT BEING ASKED TO SUBMIT A CLAIM AT THIS TIME.
  • HOWEVER, IF YOU ARE A MEMBER OF THE CLASS, YOUR RIGHTS WILL BE AFFECTED BY THIS ACTION.
  • This is a securities class action against Defendants for alleged violations of the federal securities laws.

U.S. Securities and Exchange Commission Establishes Momentus Stable Road Fair Fund

Retrieved on: 
Friday, April 5, 2024
Order, Failure, MAY, ALL, Summons, NOTE, Disclosure, READ, Fund, Treasury, Roger-Pol Droit, Form, Risk, THIS, YOU, Red Hot Organization, FAIR, Administration, Documentation, Plan, Fair Fund, Acquisition, Security (finance), Commission, PIPE, Sarbanes, NOT, Defense, ALSO, FUND, DEADLINE, Government, Cryptocurrency

The purpose of this Plan Notice is to inform you that you may be eligible to share in the proceeds of the Momentus Stable Road Fair Fund described herein.

Key Points: 
  • The purpose of this Plan Notice is to inform you that you may be eligible to share in the proceeds of the Momentus Stable Road Fair Fund described herein.
  • To be potentially eligible to share in the Momentus Stable Road Fair Fund, you must file a Claim Form in accordance with the steps set forth in this Plan Notice and in the Plan of Distribution (the "Plan") approved by the Securities and Exchange Commission ("SEC" or "Commission").
  • To qualify for a payment from the Momentus Stable Road Fair Fund, you must satisfy certain eligibility criteria that are described in detail in the Plan.
  • Additional Claim Forms and Plan Notices may also be downloaded at the Momentus Stable Road Fair Fund's website.

Blackwells Capital: Nelson Peltz is Not the Change Disney’s Board Needs

Retrieved on: 
Monday, March 25, 2024
Institutional Shareholder Services, PepsiCo, VR, IKEA, Proctor, NBC, SL Green Realty, Shareholder, International, General partnership, Proxy, Frito-Lay, ALL, Unilever, Sale, Taskrabbit, AI, City, GREEN, Warner Bros., Universal, Trustee, Procter & Gamble, NBCUniversal, Security (finance)

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Blackwells Capital, LLC (“Blackwells”), a shareholder of The Walt Disney Company (“Disney” or the “Company”) (NYSE:DIS), today released a letter to fellow Disney shareholders in connection with the Company’s Annual Meeting of Stockholders to be held on April 3, 2024, available here, at www.TheFutureOfDisney.com, and reproduced in full below:

Key Points: 
  • The Board needs directors who are independent and who will guide management into the future and contribute relevant skills and experience.
  • Blackwells and its three nominees have identified certain governance failings at Disney that they believe can be corrected by adding to the Board the talents and capabilities that Blackwells’ nominees offer.
  • The Board does not need nominees driven by personal grievances or animus towards management, as we believe Trian Partners’ (“Trian”) nominees Nelson Peltz and Jay Rasulo are.
  • Disney Shareholders – Please vote your proxy today on the GREEN universal proxy card “FOR” each of the Blackwells nominees and the Blackwells proposal.

ETFS Capital Releases Letter to Fellow WisdomTree Stockholders

Retrieved on: 
Thursday, March 21, 2024
Bitcoin, Failure, Common stock, Letter, WisdomTree Investments, ETF, ALL, Sale, Hope, Disclosure, Decentralized finance, AUM, Management

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- ETFS Capital Limited (“ETFS Capital”), the largest combined owner of common stock, $0.01 par value (the “Common Stock”), and Series A Non-Voting Convertible Preferred Stock (the “Series A Preferred Stock”) of WisdomTree, Inc. (“WisdomTree” or the “Company”) (NYSE: WT), with ownership of approximately 10.2% of the outstanding Common Stock, which together with its Series A Preferred Stock would represent approximately 18.3% of the Company’s outstanding Common Stock on an as-converted basis, today released a letter to its fellow WisdomTree shareholders, responding to a public letter from WisdomTree board of director’s (the “Board”) to ETFS Capital’s Chairman, Mr. Graham Tuckwell.

Key Points: 
  • WisdomTree Prime is and always has been a complete folly in our opinion, and in crypto ETFs the Company continues to rank towards the bottom relative to peers.
  • Consequently, WisdomTree trades at a significant discount to its intrinsic value if it were a well-run pure-play ETF business.
  • In our February 20, 2024, letter to the Board, we acknowledged that individual members of the Board and stockholders (such as ETFS Capital) have divergent views about the best way forward to unlock value at WisdomTree.
  • Fellow stockholders, over the past three years, we have attempted to address operational and governance failures through proxy campaigns.

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, March 14, 2024
Nucleus, Bone marrow, BCMA, BioNTech, B-ALL, Patient, ALL, SLE, Engineering, Minocycline, European Medicines Agency, Therapy, Research, Canadian Aviation Regulations, Flow cytometry, ASH, General counsel, Immunotherapy, SVP, EMA, Legal Affairs, Trial of the century, GMP, SME, BLA, Nature Communications, Development, UCL, Biologics license application, Multiple myeloma, MIA, University College London, Senior, TRBC, GD2, ASCO, FDA, CD19, Conference call, Conference, MAA, EHA, ADS, MHRA, T cell, ACS Chemical Biology, PDUFA, Autoimmune disease, Pharmaceutical industry

“For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.

Key Points: 
  • “For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.
  • In February 2024, Autolus promoted Dr. Chris Williams to Chief Business Officer and Alex Driggs to Senior Vice President, Legal Affairs and General Counsel.
  • Dr. Leiderman brings extensive transactional and financial expertise, and Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’ Board.
  • Financial Results for the Year Ended December 31, 2023

The American Dream: Doctors Unite to Educate About Proactive Health on "The World Wellness Show"

Retrieved on: 
Thursday, March 14, 2024
Health, Dizziness, Medicine, Education, Knowledge, ALL, Social media, Interview, DSM-IV codes, Life expectancy, Chiropractic, Host, Neuropsychology, Peptide

GAINESVILLE, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- The World Wellness Show expands collaborative movement towards proactive health to 137 countries with the help of top wellness experts.

Key Points: 
  • GAINESVILLE, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- The World Wellness Show expands collaborative movement towards proactive health to 137 countries with the help of top wellness experts.
  • Doctors wanting to share "their messages" globally and create personalized content for their clinic's social media and websites can schedule their interview now at: www.TheWorldWellnessShow.com .
  • Trish Gleason, Host of the World Wellness Show, shared: “Together we can educate the world and spark a shift in wellcare from treatment to prevention.
  • Our goal is to spark a paradigm shift to how we perceive and prioritize health and move away from reactive treatments and towards proactive wellness practices.

Current shareholder and former institutional portfolio manager, Nilesh Undavia, issues an open letter to GrafTech International Ltd. Shareholders

Retrieved on: 
Tuesday, March 12, 2024
Carbon, ACT, TSR, CFO, ALL, Tokai Carbon, IPO, HIS, Adjustment, UNIT, GrafTech, Skin, Proxy, DIRECT, WHO, ABLE, USD, Management

Since 2019 (the first full year after the IPO), GrafTech’s Revenue has declined by 65% and Adjusted EBITDA has collapsed by 98%.

Key Points: 
  • Since 2019 (the first full year after the IPO), GrafTech’s Revenue has declined by 65% and Adjusted EBITDA has collapsed by 98%.
  • Yet, the Board and management appear to have no credible strategy or plan to address the underlying failures of the core business.
  • Currently, the board has only one director out of seven total members1, with outside experience in the steel industry that GrafTech serves.
  • All of the remaining board members appear to lack relevant and transferrable expertise specific to GrafTech.

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Retrieved on: 
Tuesday, March 12, 2024
Certification, Nucleus, Patient, Orphan, ALL, MIA, EMA, GMP, MHRA, Therapy, Priority, FDA, Pharmaceutical industry

This authorisation enables Autolus to manufacture for global commercial and clinical product supply from the Nucleus effective as of March 18, 2024.

Key Points: 
  • This authorisation enables Autolus to manufacture for global commercial and clinical product supply from the Nucleus effective as of March 18, 2024.
  • Following a full site inspection in February 2024, Autolus’s Nucleus site has recently received the formal certification from the MHRA.
  • The MHRA issued two new licenses to cover both clinical and commercial manufacture from the site and found no major or critical observations in their summary report.
  • Our manufacturing team did an outstanding job qualifying, validating and taking into operation the Nucleus in record time and establishing the foundation for high quality product supply,” commented Dave Brochu, Chief Technology Officer of Autolus.